Novartis announces divestiture of influenza vaccines business to CSL for USD 275 million

29-Oct-2014 - Novartis announced it has entered into a definitive agreement to divest its influenza vaccines business to CSL Limited (CSL) for an agreed price of USD 275 million. This transaction requires regulatory approvals and is expected to close in the second half of 2015."In CSL, we have found not only ...

Albumin preserves kidney function and improves survival in abdominal infection of liver disease

25-Jan-2013 - Treatment with albumin reduces renal impairment and mortality in cirrhotic patients with spontaneous bacterial peritonitis (SBP), one of the most common bacterial infections in this patient population, according to a new meta-analysis supported by CSL Behring and published in Clinical ...

CSL Behring Initiates Study of Subcutaneous Administration of C1-esterase Inhibitor in Patients with Hereditary Angioedema

Phase I/II study to establish safety and clinical pharmacology with various doses of subcutaneous formulation of human C1-esterase inhibitor

04-May-2012 - CSL Behring announced that it has initiated an international phase I/II study of a volume-reduced, subcutaneous formulation of C1-esterase inhibitor (C1-INH) concentrate in patients with hereditary angioedema (HAE). Part of the COMPACT (Clinical Studies for Optimal Management in Preventing ...

First Patient Enrolled in CSL Behring PATH Trial to Evaluate Immune Globulin Subcutaneous (Human) 20% Liquid, Hizentra, in the Treatment of CIDP

28-Mar-2012 - CSL Behring has announced that the first patient has been enrolled in the PATH study, an international clinical trial designed to evaluate the efficacy, safety, and tolerability of two different doses of subcutaneous immunoglobulin (SCIg), compared with placebo, in maintenance treatment of ...

CSL Behring Announces First Patient Treated in Phase III Study of Fibrinogen Concentrate (Human)(FCH) to Control Bleeding During Aortic Aneurysm Surgery

19-Mar-2012 - CSL Behring announced that the first patient has been treated as part of the REPLACE Phase III clinical trial evaluating the efficacy and safety of fibrinogen concentrate (Human) (FCH) in controlling microvascular bleeding during aortic aneurysm surgery.The purpose of this study is to demonstrate ...

CSL Behring Receives EU Orphan Drug Designations for rVIIa-FP for Hemophilia A and B Treatment

01-Jun-2011 - CSL Behring announced that it has been granted Orphan Drug Designations (ODD) by the European Commission for the development of its recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP), a novel therapy to treat hemophilia A and hemophilia B patients with inhibitors. ...

CSL Behring stellt BLA-Zulassungsantrag für C1-Esterase-Inhibitor zur Behandlung des hereditären Angioödems

Zulassungsentscheidende Studie der Phase II/III zeigt, dass C1-INH bei der Behandlung akuter HAE-Attacken wirksam ist

11-Mar-2008 - CSL Behring hat bei der US-amerikanischen FDA (Food and Drug Administration) einen BLA-Antrag (Biologics License Application - Zulassungsantrag für biologische Präparate) eingereicht, um in den Vereinigten Staaten die Marktzulassung für das C1-Esterase-Inhibitor-Konzentrat des Unternehmens zur ...

Intercell: Licensure application for Japanese Encephalitis vaccine submitted to Therapeutic Goods Administration in Australia

04-Mar-2008 - Intercell AG announced the submission of application to register Intercells investigational Japanese Encephalitis vaccine in Australia to the Therapeutic Goods Administration (TGA). The submission process was executed by Intercells partner CSL Biotherapies Pty Ltd. This TGA submission has been ...

MedImmune Completes Sale of CytoGam

21-Dec-2006 - MedImmune, Inc. announced that it has completed its sale of CytoGam(R) (cytomegalovirus immune globulin intravenous (human)) to ZLB Behring. As specified in the agreement executed November 8, 2006, ZLB Behring has made a one-time upfront payment of $50 million to MedImmune, plus equipment and ...

Intercell AG and CSL Ltd. sign Exclusive Agreement for Marketing and Distribution of Japanese Encephalitis Vaccine

01-Sep-2005 - Intercell AG announced the signature of an exclusive agreement with CSL Ltd. for the Marketing and Distribution of Intercell´s novel cell culture based Japanese encephalitis vaccine in Australia. It is Intercell's first commercialization agreement for the future delivery of its lead vaccine ...